Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
55 hedge funds and large institutions have $140M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
58% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 12
11% more capital invested
Capital invested by funds: $125M → $140M (+$14.3M)
6% more funds holding
Funds holding: 52 → 55 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.71M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.69M |
| 3 |
RWA
RGT Wealth Advisors
Dallas,
Texas
|
+$1.47M |
| 4 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$1.38M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$497K |
| 2 |
JP Morgan Chase
New York
|
-$358K |
| 3 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$285K |
| 4 |
Millennium Management
New York
|
-$283K |
| 5 |
Morgan Stanley
New York
|
-$219K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $4K | -$10.1K | -407 | -72% |
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | +$3.8K | +154 | +376% |
|
53
BNP Paribas Financial Markets
Paris,
France
| $1.93K | -$4.69K | -190 | -69% |
|
|
MAM
54
Meeder Asset Management
Dublin,
Ohio
| $1K | +$741 | +30 | New |
|
55
Walleye Trading
New York
| $2 | -$51.9K | -2,100 | -95% |
|
|
UOTTAIMCU
56
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
| – | -$497K | -22,747 | Closed |
|
|
IVM
57
InterWest Venture Management
San Francisco,
California
| – | -$285K | -13,058 | Closed |
|
|
DTL
58
Dynamic Technology Lab
Singapore
| – | -$216K | -9,908 | Closed |
|
|
AIM
59
Acrospire Investment Management
Chicago,
Illinois
| – | -$68K | -3,137 | Closed |
|
RETA Hedge Fund Activity: Q1 2017 in Review
55 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q1 2017, worth a combined $140M — up 11% from $125M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RETA positions and 4 closed out — a net gain of 7 holders — while 19 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $8.71M. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), exiting entirely with an estimated $497K sold.
- 55 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q1 2017, up from 52 in Q4 2016.
- Funds reported $140M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q1 2017, up 11% quarter-over-quarter.
- 11 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q1 2017 and 4 closed out, a net change of +7 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q1 2017 was BlackRock, an estimated $8.71M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q1 2017 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $497K sold.
Based on aggregated 13F filings for Q1 2017.